Our e-Lockout device can help ensure safe and compliant drug delivery by limiting the number of doses available during a 24-hour period. Its built-in locking mechanism prevents the device from being used for a period of time after a pre-defined number of spray actuations.
Additionally, the electronic display shows the number of priming strokes, the number of doses remaining in the device, time remaining until the next dose, and whether the nasal spray is locked or ready for use.
Our e-Lockout can also incorporate specific warning features to remind patients to take their medications so that they are fully compliant in their treatment. Other features include a child-resistant cap.
Our advanced patented electronic technology may be useful in drug delivery treatment for diseases involving acute episodes, such as breakthrough pain.
Our e-Lockout technology is the only fully integrated electronic nasal drug delivery device to be approved by the European Medicines Agency (EMA).
Designed with patient safety in mind as well as ease of use, reliability and accuracy, our e-Lockout technology complies with the most stringent regulatory guidance.
Our device is tamper-proof, which is an important feature with controlled substances and for managing breakthrough pain.
We have a broad and growing range of innovative connected solutions and platforms.
Our digital healthcare solutions can either be integrated into or added-on to any of our existing drug delivery devices, which is the broadest range in the industry.
As global leaders in proven nasal drug delivery solutions, we can help you develop safe solutions for patients. Why not speak to one of our experts today?
© 2026 Aptar.com. All rights reserved.